

ersonal use only



The Next Generation of Wellness Your Life Deserves

IMPORTANT: You must read the following disclaimer before continuing. The information contained in this presentation (including any accompanying oral presentation, question and answer session and any other document or materials distributed at or in connection with this presentation) (the "**Presentation**") is provided for introductory discussion purposes only and is strictly confidential. This Presentation is furnished to you on a confidential basis solely for the purpose of evaluating your interest in this opportunity. By its acceptance hereof, each recipient agrees that neither it nor its agents, representatives, directors or employees (the "**Recipients**") will copy, reproduce or distribute to others this Presentation, in whole or in part, at any time without the prior written consent of Wellnex Life Limited ("**Wellnex**" or the "**Company**") and that it will keep confidential this Presentation or any information otherwise obtained from the Company and will use this Presentation for the sole purpose of evaluating a possible investment in the Company. This Presentation is being made available to the Recipients for the sole purpose of providing information to the Recipients on the Company and is not intended to form the basis of any investment activity or decision, and should not be considered as a recommendation by the Company that any Recipient should acquire any interest in the share capital or in any other interest in the Company.

The distribution of this Presentation in certain jurisdictions may be restricted by law and therefore persons into whose possession this Presentation comes should inform themselves about and observe such restrictions. Any person who receives this Presentation in violation of such restrictions should not act upon it and should return it to the Company immediately. The Presentation is not directed to, or intended for distribution for use by any persons or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. In particular, this Presentation (and the information contained in it) is not for release, publication or distribution, directly or indirectly, in the United States (or for the account of any "U.S. Person" as defined in Regulation S under the US Securities Act 1933), Australia, New Zealand, Canada, Japan or the Republic of South Africa.

This Presentation does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. It does not constitute or form part of and should not be relied upon in connection with any offer or invitation to sell or issue, or a solicitation of an offer or invitation to purchase or subscribe for, any securities or other interests in the Company or any related entity and no legal relations shall be created by its issue. The information set out in this Presentation shall not form the basis of any prospectus, contract or commitment whatsoever and should not be relied upon in relation to any prospectus, contract or commitment. The information contained in this Presentation does not and is not intended to constitute a "valuation," "formal valuation," "appraisal," "prior valuation," or a "report, statement or opinion of an expert" for purposes of any securities legislation in the UK or elsewhere.

This Presentation does not purport to cover all matters that may be relevant for the purposes of considering whether or not to make any prospective investment. Each Recipient acknowledges that it will be solely responsible for its own assessment of the relevant market and the market position of the Company, it will conduct its own analysis and obtain its own professional advice and be solely responsible for forming its own view of the business and financial condition of the Company and the Company's potential future performance. The information contained in this Presentation is provided on the basis that independent enquiries will be made by the Recipient.

This Presentation does not comprise nor contain all the information that would be required for an AIM admission document or a prospectus relating to the Company nor does it give or purport to give legal, tax or financial advice. The contents of this Presentation have not been examined or approved by the Financial Conduct Authority, London Stock Exchange plc ("**LSE**") or any other regulator, nor is it intended that the Presentation will be so examined or approved. At present, no decision has been made to proceed with the Placing and/or Admission (as defined below) and this Presentation should not be taken as any form of commitment on behalf of the Company to proceed with any transaction. If a decision is made to proceed, Recipients of this Presentation who intend to subscribe for or purchase securities in the Company are reminded that any such subscription or purchase may only be made on the basis of the information and terms and conditions contained in the AIM admission document and any supplementary AIM admission document to be issued by the Company in connection with Admission and must be made on the basis of their own judgement as to the merits of the Company and the suitability of the shares in the Company for their purposes, having taken all such professional or other advice as they consider necessary or appropriate in the circumstances.

Strand Hanson Limited ("**Strand Hanson**"), which is a member firm of the LSE, is authorised and regulated by the FCA and is acting as nominated adviser to the Company in connection with the proposed placing (the "**Placing**") of ordinary shares ("**Ordinary Shares**") in the capital of the Company and the proposed application for the admission ("**Admission**") of all the issued and to be issued Ordinary Shares to trading on the AIM market operated by the LSE. Strand Hanson is not acting for any person other than the Company in connection with the Admission, and will not be responsible to any person other than the Company for providing the protections afforded to its customers or for advising any other person in relation to the Admission, the contents of this Presentation or on any transaction or arrangement referred to in this Presentation. Strand Hanson's responsibilities as the Company's nominated adviser under the AIM Rules for Companies and the AIM Rules for Nominated Advisers are owed solely to the LSE and are not owed to the Company, any director of the Company or to any other person (whether in connection with a decision to subscribe for or acquire any Ordinary Shares or otherwise). Strand Hanson has not authorised the contents of this Presentation (or any part of it) and no representation or warranty, express or implied, is made by Strand Hanson as to, and no liability is accepted by Strand Hanson in respect of, any of the contents of this Presentation.

Orana Corporate LLP ("**Orana**") is a member firm of the LSE, authorised and regulated by the FCA. S.P. Angel Corporate Finance LLP ("**SP Angel**") is a member firm of the LSE, authorised and regulated by the FCA. Orana and SP Angel are acting as joint brokers to the Company (the "**Brokers**"). The Brokers are not acting for any person other than the Company in connection with the Placing, and will not be responsible to any person other than the Company for providing the protections afforded to its customers or for advising any other person on the Placing, Admission, the contents of this Presentation or on any transaction or arrangement referred to in this Presentation. The Brokers' responsibilities as the Company's joint brokers under the AIM Rules for Companies are owed solely to the LSE and are not owed to the Company, any director of the Company or any other person (whether in connection with a decision to subscribe for or acquire any Ordinary Shares or otherwise). The Brokers have not authorised the contents of this Presentation (or any part of it) and no representation or warranty, express or implied, is made by the Brokers as to, and no liability is accepted by the Brokers in respect of, any of the contents of this Presentation.

This Presentation may only be communicated or caused to be communicated in the UK to: (1) persons authorised to carry on a regulated activity under the Financial Services and Markets Act 2000 ("**FSMA**"); (2) persons in the UK who are both (A) "qualified investors" within the meaning of Article 2(e) of the Prospectus Regulation (EU) 2017/1129 as it forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018 (as amended) and (B) are either: (i) persons having professional experience in matters relating to investments and qualifying as investment professionals under Article 19 of the FSMA (Financial Promotion) Order 2005, as amended (the "**Order**"); (ii) persons qualifying as high net worth individuals under Article 48 of the Order; (iii) persons qualifying as high net worth companies or unincorporated associations under Article 49 of the Order; (iv) persons contemplated by Article 62 of the Order; or (v) any other persons to whom this Presentation may otherwise lawfully be communicated or caused to be communicated ("**Relevant Persons**"). This Presentation is exempt from the general restriction in Section 21 of the FSMA on the grounds that it is made to a Recipient who is a Relevant Person. The contents of this Presentation have not been approved for distribution in the UK by an authorised person which would be required pursuant to Section 21 of the FSMA if this Presentation were to be distributed to persons other than Relevant Persons. Recipients who are not Relevant Persons should not rely on this Presentation nor take any action upon this Presentation, but should return it immediately to the Company. Reliance on this Presentation for the purpose of engaging in any investment activity may expose the Recipient to a significant risk of losing all of the property invested.

This Presentation includes certain projections and forward-looking statements with respect to Wellnex's operations, economic performance and financial condition. Such projections and forward-looking statements reflect various assumptions of management concerning the future performance of the Company, which assumptions may or may not prove to be correct. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Wellnex's actual results, performance or achievements to differ materially from the anticipated results, performance or achievements expressed or implied in these forward-looking statements. Although Wellnex believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. The actual results may vary from the anticipated results and the results could differ materially from those set out in the forward-looking statements as a result of, among other factors, changes in economic, social, political and market conditions, success of business and operating initiatives, changes in the regulatory environment and other government actions including environmental approvals and actions, fluctuations in metals prices and exchange rates, and business and operational risk management. Interested parties should use caution and consider these factors in evaluating any such forward-looking statements. The information contained in this Presentation, including the forward-looking statements, speak only as at the date of this Presentation. The Company is not obliged, and does not intend, to update or correct any inaccuracies in this Presentation or release any forward-looking statements, whether as a result of new information, future events or otherwise except to the extent required by any applicable law or regulation.

AN INVESTMENT IN THE COMPANY INVOLVES RISK. SEVERAL FACTORS COULD CAUSE THE ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF THE COMPANY TO BE MATERIALLY DIFFERENT FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS THAT MAY BE PREDICTED OR IMPLIED BY STATEMENTS AND INFORMATION IN THIS PRESENTATION. SHOULD ONE OR MORE OF THESE RISKS OR UNCERTAINTIES MATERIALISE, OR SHOULD UNDERLYING ASSUMPTIONS PROVE INCORRECT, THE ACTUAL RESULTS OF THE COMPANY MAY VARY MATERIALLY FROM THOSE FORECASTED IN THIS PRESENTATION.

This Presentation may contain certain "Non-GAAP" financial measures. In addition, the presentation of these measures may not be comparable to similarly titled measures other companies may use.

No representation, warranty or undertaking, express or implied, or liability or duty of care is or will be given by the Company, Strand Hanson, the Brokers or their respective directors, officers, employees, partners, agents, representatives or advisers as to the fairness, reliability, omission of, or reasonableness, accuracy or completeness of the information or opinions in the Presentation or any other written or oral information made available to any interested party or its advisers, without prejudice to any liability for, or remedy in respect of, fraudulent misrepresentation. In particular, but without prejudice to the generality of the foregoing, no representation or warranty is given as to the achievement or reasonableness of any future projections, management estimates, prospects or returns contained in the Presentation. To the fullest extent possible, by accessing, attending or receiving this Presentation each Recipient releases the Company, Strand Hanson, the Brokers and each of their respective directors, officers, employees, partners, agents, representatives or advisers in all circumstances (other than fraud) from any liability. Accordingly, the Company, Strand Hanson, the Brokers and each of their representatives shall not be liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on any statement in or omission from the Presentation.

STRICTLY PRIVATE AND CONFIDENTIAL

WELLNEX LIFE

Executive Directors

A wealth of experience in healthcare and fast-moving consumer goods



Zack Bozinovski
Managing Director

- Over 35 years of senior experience within Fast Moving Consumer Goods (FMCG) and Pharmaceutical companies in Australia and internationally.
- Held senior positions at PepsiCo, Nestlé (Uncle Tobys) and Sigma Pharmaceuticals.
- Successfully developed established and owned brands, including Voöst Vitamins, (sold to Proctor & Gamble in April 2021)
- As owner, sold Brand Solutions, an Australian brokerage business to Wellnex Life in July 2021
- Commenced with Wellnex Life in July 2021



George Karafotias
Chief Executive Officer

- Specialist in restructuring, reinventing and implementing turnaround strategies for various ASX-listed companies with great success
- Established track record with publicly-traded businesses, predominantly in senior executive positions.
- Appointed CEO of Wellnex Life in July 2021

Company Highlights

Major transition

Transitioned from a low margin brokerage business to a high margin branded business

Improving financials

Revenue and margin growth on pathway to profitability

Strong client base

Established relationships with leading retailers

High demand products

Scientifically formulated products with clinical evidence developed for fast growing consumer markets and categories

Global partnerships

Licensing arrangement with-Haleon to supply Wellnex Life developed products globally for leading pain relief brand

Omnichannel strategy

Products represented throughout 8,000 grocery and pharmacy doors and online

Strong revenue growth

Revenue growth of 112% for the 1HFY25 compared to 1HFY24, with brand revenue up 182% in the same period

Growth opportunities

Further expansion opportunities in international market with branded business and IP licensing.

Experienced management & board

Decades of experience in healthcare and FMCG supported by a diverse skills matrix

ersonal use only

Company Profile & Owned Brand Portfolio

Company History

ersonal use only



Company Asset Portfolio

WELLNEXLIFE



ersonal use only

Owned Brands

Our Innovative Market Leading Products



Pain Away

Australia's No 1* topical liquid pain relief brand containing arnica specifically formulated for joints and topical pain

ACQUIRED: December 2023



Wakey Wakey

Caffeine & Guarana Effervescent Complementary Medicine boosting energy levels


LAUNCHED: Oct 21



Nighty Night

Ashwagandha Effervescent Complementary Medicine helping you to fall asleep faster

LAUNCHED: July 2023



The Iron Company

Complementary Medicinal Iron gummy with Slow-Release Technology for the relief of tiredness & fatigue

LAUNCHED: Sept 2021



Mr Bright

Natural teeth whitening products without harmful hydrogen peroxide that whitens teeth up to eight shades

ACQUIRED: December 2022

Owned Brands

Pain Away

No1. Topical pain relief brand containing Arnica

- Completed acquisition for A\$20.85 million, on compelling metrics of 1.5x revenue and 6.3x EBITDA (FY23)
- All products are listed with the Therapeutic Goods Administration (TGA)
- High gross margins
- Extensive distribution in Australian market within pharmacy and grocery stores
- 84% of revenue derived from pharmacy thus further scope to increase in grocery
- Export growth opportunities identified into Asia, Europe and New Zealand. (First NZ export sales recorded in 1HFY25)



Owned Brands

Wakey Wakey and Nighty Night


Wakey Wakey is an Australian Complementary Caffeine & Guarana Effervescent Medicine boosting energy levels.

Nighty Night is an Australian Complementary Ashwagandha Effervescent Effervescent Medicine helping you to fall asleep faster.

- Revenue growth of **152% in FY24** compared to FY23
- Australian pharmacy and grocery vitamin category valued at over **A\$1.7B** (IQVIA Sep 24) with energy and sleep/stress one of the major sub segments
- Strong gross margins
- Potential export growth opportunities into Europe and New Zealand

**WAKEY
WAKEY**

**NIGHTY
NIGHT**



Distribution Capabilities

You can find a Wellnex Life product in over 95% of Australia's grocery and pharmacy doors...and in the UK.

Australian Grocery & Pharmacy Retailers and Wholesalers - Approx 8,000 Doors



International Distributors



Supply Agreements



July to December 2024 Highlights



Strong Financial Performance

- ✓ H1FY25 total revenue up **112%** compared to H1FY24
- ✓ H1FY25 branded revenue up **182%** compared to H1FY24
- ✓ H1FY25 IP licensing revenue up **64%** compared to H1FY24
- ✓ Increasing brand investment
- ✓ Record **A\$3M** revenue in each month November and December 2024

Branded Business


- ✓ Continued brand growth
- ✓ Incremental Pain Away distribution into New Zealand and supermarkets in Australia
- ✓ 100% of resources focused on owned brands
- ✓ Strong NPD pipeline development for 2025

Licensing Growth

- ✓ Haleon launch UK
- ✓ Additional Ibuprofen Mini soft gel launches in Chemist Warehouse (3 lines)
- ✓ Additional Paracetamol soft gel launches in Arrotex (4 lines)
- ✓ Continued global dialogue for launches of additional lines in additional countries

Domestic and International Growth Strategy

Personal use only



ersonal use only

Company Profile
Licensed Brands

Licensing Contracts

“A world leading consumer health company with clear purpose to deliver better everyday health with humanity”

HALEON

Partnership Milestones


Initial discussions March 2021

HALEON DD conducted, WNX signs supply agreement March 2022

Marketing Authorisation (MA) approval received with lines launched in Australia in May 2022

Success of Australian launch resulted in UK launch

New country and new product discussions continually ongoing



Partnership Details

HALEON Australia issued With MA to launch Paracetamol Soft Gel in January 2022

Australian MA utilised to support UK Paracetamol MHRA approval in February 2024

Without Wellnex's MA, Haleon CANNOT market and sell the Soft Gels

Initially signed 3-year contract which was recently extended

HALEON place orders with WNX who in turn place order With WNX manufacturing partner

Licensing Contracts

In licensing and supply agreement with Australia's largest generic drug manufacturer, a division of DBG group a company with **\$1.5b** revenue




Partnership Milestones

Initial discussions March 2021

4 lines supplied in Australia under Chemist Own & Apo Health Brands

Launch of new lines of Paracetamol Liquid Soft Gels in July 2024

Ongoing discussions for additional products



Partnership Details

WNX issued Marketing Authorisation (MA) to launch Soft Gels in Dec 23 & Jan 24

Without Wellnex's MA Arrotex CANNOT market and sell the Soft Gels

Contract to July 2025 with an automatic 12 month extension

Arrotex place order with WNX who in turn place order with WNX manufacturing partner

Licensing Contracts

Chemist Warehouse (CWH) is a leading Australian retail pharmacy franchisor and owns the 'Chemist Warehouse and My Chemist pharmacy franchise brands with annual revenue of **\$9b** in CY24



Partnership Milestones

CWH own the Wagner Brand and WNX owns the LIQUIGESIC brand

Jointly owned Wagner LIQUIGESIC agreement signed in 2021

Wagner Liquigesic launched in market in March 2022 as the First Liquid Soft Gels Brand

Agreement in March 2024 to launch 3 lines of Ibuprofen Mini Liquid Soft Gels



Partnership Details

WNX issued Marketing Authorisation (MA) to launch Soft Gels in Dec 23 & Jan 24

WNX Issues CWH With A Marketing Authorisation To Launch Soft Gels in Nov 20 and Jan 24

Without Wellnex's MA CWH CANNOT market and sell the Soft Gels

WNX responsible for procurement and CWH responsible for brand consumer marketing

CWH place order with WNX who in turn place order with WNX manufacturing partner



ersonal use only

WELLNEXLIFE

ersonal use only

Development Pipeline



Australian Therapeutic Goods Administration (TGA)



Australian Government

Department of Health and Aged Care
Therapeutic Goods Administration

Australia's government authority responsible for evaluating, assessing and monitoring products that are defined as therapeutic goods whilst also regulating medicines, medical devices and biologicals to help Australians stay healthy and safe.

Delivers strong guidelines around regulations associated with **advertising** therapeutic goods


Information to assist manufacturers understand their **regulatory responsibilities**

Information on types of and permissible **ingredients** and poisons standards


Provides guidelines around **importing** and **exporting** therapeutic goods

Ensures **labelling** and **packaging** meets the strict domestic requirements

Formulating and Launching Complimentary & Registered Medicines With The Therapeutic Goods Administration (TGA)



World Class Development Pipeline



Personal use only

WELLNEXLIFE

Financial Overview


Financial Information

Brand Revenue Growth and Expanding Margins


Wellnex Life portfolio of 100% owned brands are high gross margin products that are rapidly growing

- First WNX brands launched in FY22
- First Half FY25 revenue of **A\$12m** puts WNX on track to continue high growth trajectory
- Management expectations for continued growth in revenue and margins across WNX brands in H2 FY25 and FY26 as brand awareness continues to build and new geographic markets become accessible

Historical Revenue



Historical Gross Profit & Margin



Financial Information

Company Shares on Issue and Funds Use

Capital Structure

Shares on Issue	30,517,231
Option: Exp 1-Jan-26, Ex A\$2.50	1,400,000
Option: Exp 6-Feb-26, Ex A\$7.50	146,316
Option: Exp 20-Jul-25, Ex A\$5.00	550,000
Option: Exp 30-Jun-25, Ex A\$2.50	4,369,418
Fully Diluted Shares	36,982,965
2 Convertible Notes – Amount – A\$6.4 million Coupon – 13% Expiring – 21 June 2025 Conversion – A\$4.00 (option to convert at IPO price on admission to AIM)	

Estimated Use Of Proceeds

PA – Deferred Consideration	£3,100,000	38.8%
(Redemption of Notes)	(£3,200,000)	(40.0%)
Working Capital	£850,000	10.6%
Cost of Offer	£850,000	10.6%
Total	£8,000,000	100%

Investment Summary

Why it is a great time to invest in **WELLNEXLIFE**



Proven growth

Growing revenue from high value and margin branded business both in Australia and internationally.



International expansion

Commencement of international sales into the UK with Haleon will further drive the revenue and profitability and capitalise on further international expansion.



Strong partnerships

Agreements with leading global and Australian consumer healthcare companies that continue to validate the business model.



Innovative pipeline

Strong pipeline of innovative products for branded and contract business to diversify growth streams.



Experienced leadership

Experienced board and management team focused on maximising the opportunities in Australia and internationally.

ersonal use only

The Next Generation of Wellness Your Life Deserves

**For further information
please contact:**
Wellnex (ASX:WNX)
George Karafotias
Chief Executive Officer
P: +61 3 8399 9419
E: george.k@wellnexlife.com.au

WELLNEXLIFE

Contact Us



Orana Corporate LLP
Seb Wykeham
P: +44 203 475 6834



SP Angel Corporate Finance LLP
Vadim Alexandre/David Hignell
P: +44 203 470 0470

ersonal use only